Blood oxytocin levels and the rs4686302 polymorphism of the oxytocin receptor gene in patients with adenomyosis

Abstract

BACKGROUND: An in-depth study of the pathogenesis of adenomyosis and the development of new therapeutic approaches are extremely relevant. Atosiban, a competitive oxytocin receptor antagonist, may be a promising drug with a potential therapeutic effect. Oxytocin is involved in the pathogenesis of adenomyosis-associated dysmenorrhea, and there is evidence of increased expression of the oxytocin receptor (OXTR) in the myometrium in adenomyosis and the association of the OXTR gene polymorphic variant rs4686302 with oxytocin-induced myometrial contractility.

AIM: The aim of this study was to evaluate blood oxytocin levels and the frequency of the polymorphic variants of the oxytocin receptor gene (OXTR) rs4686302 polymorphism in patients with adenomyosis and in healthy women of reproductive age.

MATERIALS AND METHODS: The levels of oxytocin in the blood plasma were measured by competitive enzyme immunoassay (ELISA) in patients with adenomyosis (n = 56, with mean age of 37.5 ± 8.54 years), and in women without gynecological diseases (control group; n = 33, with mean age of 32.1 ± 5.40 years). The polymorphic variant rs4686302 of the OXTR gene was analyzed by PCR-RFLP analysis in patients with adenomyosis (n = 79, with mean age of 39.9 ± 7.74 years) and in control group patients (n = 49, with mean age of 37.0 ± 9.20 years). The chi-square (χ²) test was used to analyze the distribution of genotypes and alleles. Statistical data processing was performed using the Jamovi Software, Version 1.2.27 for Windows.

RESULTS: In patients with adenomyosis, the level of oxytocin in the blood serum was significantly higher than in control group patients: 130.0 ± 27.9 pg/ml and 95.9 ± 26.7 pg/ml, respectively. The minor allele A of the OXTR gene polymorphic variant rs4686302 was significantly more common in patients with adenomyosis (28.5%) than in women in the control group (13.3%) and in the general sample (11–15% according to the 1000 Genomes Project). The odds of developing adenomyosis in patients with the presence of the A allele (the G/A and A/A genotypes) were 2.44 times higher compared to patients with the G/G genotype (OR 2.44, 95% CI 1.13–5.28).

CONCLUSIONS: The data obtained suggest the participation of oxytocin and its receptor in the pathogenesis of adenomyosis and requires further research in this direction.

Keywords

adenomyosis / oxytocin / oxytocin receptors / gene polymorphism / oxytocin receptor gene

References

[1] Benagiano G, Brosens I. History of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):449–463. DOI: 10.1016/j.bpobgyn.2006.01.007

[2] Benagiano G., Brosens I. History of adenomyosis // Best Pract. Res. Clin. Obstet. Gynaecol. 2006. Vol. 20. No. 4. P. 449–463. DOI: 10.1016/j.bpobgyn.2006.01.007

[3] Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012;27(12):3432–3439. DOI: 10.1093/humrep/des332

[4] Naftalin J., Hoo W., Pateman K., et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic // Hum. Reprod. 2012. Vol. 27. No. 12. P. 3432–3439. DOI: 10.1093/humrep/des332

[5] Maheshwari A, Gurunath S, Fatima F, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–392. DOI: 10.1093/humupd/dms006

[6] Maheshwari A., Gurunath S., Fatima F., et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes // Hum. Reprod. Update. 2012. Vol. 18. No. 4. P. 374–392. DOI: 10.1093/humupd/dms006

[7] Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108(3):483–490.e3. DOI: 10.1016/j.fertnstert.2017.06.025

[8] Younes G., Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis // Fertil. Steril. 2017. Vol. 108. No. 3. P. 483–490. DOI: 10.1016/j.fertnstert.2017.06.025

[9] Juang CM, Chou P, Yen MS, et al. Adenomyosis and risk of preterm delivery. BJOG. 2007;114(2):165–169. DOI: 10.1111/j.1471-0528.2006.01186.x

[10] Juang C.M., Chou P., Yen M.S., et al. Adenomyosis and risk of preterm delivery // BJOG. 2007. Vol. 114. No. 2. P. 165–169. DOI: 10.1111/j.1471-0528.2006.01186.x

[11] Hashimoto A, Iriyama T, Sayama S, et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med. 2018;31(3):364–369. DOI: 10.1080/14767058.2017.1285895

[12] Hashimoto A., Iriyama T., Sayama S., et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition // J. Matern. Fetal. Neonatal. Med. 2018. Vol. 31. No. 3. P. 364–369. DOI: 10.1080/14767058.2017.1285895

[13] Scala C, Leone Roberti Maggiore U, Racca A, et al. Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. Ultrasound Obstet Gynecol. 2018;52(5):666–671. DOI: 10.1002/uog.18989

[14] Scala C., Maggiore U.L.R., Racca A., et al. Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis // Ultrasound. Obstet. Gynecol. 2018. Vol. 52. No. 5. P. 666–671. DOI: 10.1002/uog.18989

[15] Bertucci E, Sileo FG, Diamanti M, et al. How adenomyosis changes throughout pregnancy: a retrospective cohort study. Int J Gynaecol Obstet. 2023;160(3):856–863. DOI: 10.1002/ijgo.14383

[16] Bertucci E., Sileo F.G., Diamanti M., et al. How adenomyosis changes throughout pregnancy: a retrospective cohort study // Int. J. Gynaecol. Obstet. 2022. Vol. 160. P. 956–863. DOI: 10.1002/ijgo.14383

[17] Gordts S, Grimbizis G, Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. Fertil Steril. 2018;109(3):380–388.e1. DOI: 10.1016/j.fertnstert.2018.01.006

[18] Gordts S., Grimbizis G., Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis // Fertil. Steril. 2018. Vol. 109. No. 3. P. 380–388. DOI: 10.1016/j.fertnstert.2018.01.006

[19] Gao X, Outley J, Botteman M, et al. Economic burden of endometriosis. Fertil Steril. 2006;86(6):1561–1572. DOI: 10.1016/j.fertnstert.2006.06.015

[20] Gao X., Outley J., Botteman M., et al. Economic burden of endometriosis // Fertil. Steril. 2006. Vol. 86. No. 6. P. 1561–1572. DOI: 10.1016/j.fertnstert.2006.06.015

[21] Yarmolinskaya MI, Shalina MA, Khachaturyan AR, et al. Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy. Obstetrics and Gynecology. 2020;(3):182–190. (In Russ.) DOI: 10.18565/aig.2020.3.182-190

[22] Ярмолинская М.И., Шалина М.А., Хачатурян А.Р., и др. Аденомиоз: от научных открытий к практическим аспектам назначения медикаментозной терапии // Акушерство и гинекология. 2020. № 3. С. 182–190. DOI: 10.18565/aig.2020.3.182-190

[23] Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril. 2013;99(1):231–240. DOI: 10.1016/j.fertnstert.2012.08.038

[24] Guo S.W., Mao X., Ma Q., et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis // Fertil. Steril. 2013. Vol. 99. No. 1. P. 231–240. DOI: 10.1016/j.fertnstert.2012.08.038

[25] Orazov MR, Radzinsky VE, Lokshin V N, et al. The role of oxytocin and vasopressin receptors in the pathogenesis of pelvic pain caused by adenomyosis. Patologicheskaya fiziologiya i eksperimental’naya terapiya. 2019;63(2):99–107. (In Russ.) DOI: 10.25557/0031-2991.2019.02.99-107

[26] Оразов М.Р., Радзинский В.Е., Локшин В.Н., и др. Роль рецепторов к окситоцину и вазопрессину в патогенезе тазовой боли, обусловленной аденомиозом // Патологическая физиология и экспериментальная терапия. 2019. Т. 63. № 2. С. 99–107. DOI: 10.25557/0031-2991.2019.02.99-107

[27] Akerlund M. The role of oxytocin and vasopressin in the initiation of preterm and term labour as well as primary dysmenorrhoea. Regul Pept. 1993;45(1–2):187–191. DOI: 10.1016/0167-0115(93)90204-l

[28] Akerlund M. The role of oxytocin and vasopressin in the initiation of preterm and term labour as well as primary dysmenorrhoea // Regulatory Peptides. 1993. Vol. 45. No. 1–2. P. 187–191. DOI: 10.1016/0167-0115(93)90204-l

[29] Akerlund M, Melin P, Maggi M. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Adv Exp Med Biol. 1995;395:595–600.

[30] Akerlund M., Melin P., Maggi M. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea // Adv. Exp. Med. Biol. 1995. Vol. 395. P. 595–600.

[31] Steinwall M, Bossmar T, Gaud C, et al. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. Acta Obstet Gynecol Scand. 2004;83(1):12–18. DOI: 10.1111/j.1600-0412.2004.00320.x

[32] Steinwall M., Bossmar T., Gaud C., et al. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women // Acta Obstet. Gynecol. Scand. 2004. Vol. 83. No. 1. P. 12–18. DOI: 10.1111/j.1600-0412.2004.00320.x

[33] Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res. 2002;139:359–365. DOI: 10.1016/s0079-6123(02)39030-7

[34] Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea // Prog. Brain. Res. 2002. Vol. 139. P. 359–365. DOI: 10.1016/s0079-6123(02)39030-7

[35] Richter ON, Tschubel K, Schmolling J, et al. Immunohistochemical reactivity of myometrial oxytocin receptor in extracorporeally perfused nonpregnant human uteri. Arch Gynecol Obstet. 2003;269(1):16–24. DOI: 10.1007/s00404-003-0474-0

[36] Richter O.N., Tschubel K., Schmolling J., et al. Immunohistochemical reactivity of myometrial oxytocin receptor in extracorporeally perfused nonpregnant human uteri // Arch. Gynecol. Obstet. 2003. Vol. 269. No. 1. P. 16–24. DOI: 10.1007/s00404-003-0474-0

[37] Richter ON, Bartz C, Dowaji J, et al. Contractile reactivity of human myometrium in isolated non-pregnant uteri. Hum Reprod. 2006;21(1):36–45. DOI: 10.1093/humrep/dei295

[38] Richter O.N., Bartz C., Dowaji J., et al. Contractile reactivity of human myometrium in isolated non-pregnant uteri // Hum. Reprod. 2006. Vol. 21. No. 1. P. 36–45. DOI: 10.1093/humrep/dei295

[39] Lesny P, Killick SR. The junctional zone of the uterus and its contractions. BJOG. 2004;111(11):1182–1189. DOI: 10.1111/j.1471-0528.2004.00350.x

[40] Lesny P., Killick S.R. The junctional zone of the uterus and its contractions // BJOG. 2004. Vol. 111. No. 11. P. 1182–1189. DOI: 10.1111/j.1471-0528.2004.00350.x

[41] Mechsner S, Grum B, Gericke C, et al. Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril. 2010;94(7):2541–2546. DOI: 10.1016/j.fertnstert.2010.03.015

[42] Mechsner S., Grum B., Gericke C., et al. Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adeno myosis uteri // Fertil. Steril. 2010. Vol. 94. No. 7. P. 541–2546. DOI: 10.1016/j.fertnstert.2010.03.015

[43] Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010;202(4):346.e1–346.e3468. DOI: 10.1016/j.ajog.2009.11.035

[44] Nie J., Liu X., Guo S.W. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis // Am. J. Obstet. Gynecol. 2010. Vol. 202. No. 4. P. 346.e1–346.e8. DOI: 10.1016/j.ajog.2009.11.035

[45] Zhang Y, Yu P, Sun F, et al. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis. Acta Obstet Gynecol Scand. 2015;94(4):412–418. DOI: 10.1111/aogs.12595

[46] Zhang Y., Yu P., Sun F., et al. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis // Acta Obstet. Gynecol. Scand. 2015. Vol. 94. No. 4. P. 412–418. DOI: 10.1111/aogs.12595

[47] Kim J, Stirling KJ, Cooper ME, et al. Sequence variants in oxytocin pathway genes and preterm birth: a candidate gene association study. BMC Med Genet. 2013;14:77. DOI: 10.1186/1471-2350-14-77

[48] Kim J., Stirling K.J., Cooper M.E., et al. Sequence variants in oxytocin pathway genes and preterm birth: a candidate gene association study // BMC Med. Genet. 2013. Vol. 14. P. 77. DOI: 10.1186/1471-2350-14-77

[49] Füeg F, Santos S, Haslinger C, et al. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study. BMC Med Genet. 2019;20(1):178. DOI: 10.1186/s12881-019-0894-8

[50] Füeg F., Santos S., Haslinger C., et al. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study // BMC medical genetics. 2019. Vol. 20. No. 1. P. 1–7. DOI: 10.1186/s12881-019-0894-8

[51] He Y, Wu H, He X, et al. Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study. Fertil Steril. 2016;106(2):416–422. DOI: 10.1016/j.fertnstert.2016.04.019

[52] He Y., Wu H., He X., et al. Administration of atosiban in patients with endometriosis undergoing frozen–thawed embryo transfer: a prospective, randomized study // Fertil. Steril. 2016. Vol. 106. No. 2. P. 416–422. DOI: 10.1016/j.fertnstert.2016.04.019

RIGHTS & PERMISSIONS

Eсо-Vector